tbuckley/cabot-search huggingface dataset:
FRI0171 Obesity contributes to suboptimal physical function in rheumatoid arthritis
Authors: A Sirois, N Chiarlitti, M Inceer, M Jones, CO Bingham, SJ Bartlett
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Aggressive, early treatment of RA with new therapeutic agents has dramatically improved the management of RA. However, many studies have failed to show greater improvements in function or disability reduction between targeted control vs. less-aggressive care. The prevalence of obesity is increasing dramatically globally, and may be even higher in RA patients.<sup>1</sup> <h3>Objectives</h3> Because obesity is also a risk factor for disability, we evaluated the extent to which excess weight may independently contribute to poorer physical function (PF) in RA. <h3>Methods</h3> RA patients enrolled in an observational study at an academic Inflammatory Arthritis Clinic in Baltimore USA completed the patient global, pain VAS, and PROMIS measures assessing PF, pain, fatigue, sleep, and depression. RA clinical indicators were also collected at the visit. Outcomes were compared in obese and non-obese patients using t-tests and chi-square. Multiple regression was used to evaluate the effects of pain, fatigue, and BMI on PF, after controlling for age and disease activity. <h3>Results</h3> Participants were mostly female (82%) and white (83%) with mean (SD) age of 55 (13) years; 24% had ≤ high school; RA duration 12 (9). Mean CDAI was 8.1 (8.1). Most were in CDAI remission (n=57; 32%) or LDA (n=64; 36%); 40 (23%) were in MDA and 16 (9%) in HDA. 49 (28%) were classified as normal weight (BMI 18.5–24.9), 46 (26%) were overweight (BMI 25–29.9), and 82 (46%) were obese (BMI≥30). Men had a significantly higher mean BMI than women (33.6 [8.4] vs. 29.5 [7.2], p=0.006). As compared to non-obese participants, obese participants had a significantly (p&lt;.05) higher CDAI (6.1 [6.9] vs. 10.4 [8.9]; p=.000, respectively) and worse PF, pain, fatigue, sleep, and depression (mean differences -5.0, -4.6, 4.6, 3.8, 2.9, 3.6, and -4.7, respectively). In regression analyses, pain, fatigue, and BMI (but not sleep or depression) were inversely related to PF, after controlling for age and disease activity. In the final model, pain, fatigue and BMI were significantly and inversely related to PF (β=-.39, -.24, and -.153, respectively) after controlling for age and disease activity (F (5, 170) =55.5, p=.000, adjusted r<sup>2</sup>=.61). <h3>Conclusions</h3> Our results suggest that excess weight also contributes to poorer PF in addition to pain and fatigue. As the prevalence of obesity continues to escalate in RA populations, weight loss may be increasingly important to improve not only physical health, disease activity, and response to treatment, but also pain, fatigue, and PF. <h3>References</h3> Colmegna et al. High rates of obesity and greater associated disability among people with rheumatoid arthritis in Canada. Clin Rheumatol 2016;35(2):457–60. <h3>Acknowledgements</h3> Funding: PCORI IP2-PI0000737 and SC14–1402–10818, CIHR 312205. <h3>Disclosure of Interest</h3> None declared
Cenicriviroc placebo for the treatment of non-alcoholic steatohepatitis with liver fibrosis: Results from the Year 1 primary analysis of the Phase 2b CENTAUR study
Authors: Arun J. Sanyal, Frank Tacke, Laurent Fischer, Jeffrey Vest, Vlad Ratziu, Star Seyedkazemi, Sven M. Francque, Brian L. Wiens, Guruprasad P. Aithal, Manal F. Abdelmalek, Krzysztof Simon, Scott L. Friedman, Pamela Vig, Juan Caballeria, Stephen Harrison, Vincent W. Wong, Antonio Craxi, Geoffrey C. Farrell, Zachary D. Goodman, Liza Melchor-Khan, Kris V. Kowdley, Rohit Loomba, Eric Lefebvre
Journal: Hepatology (2016)
AB0898 Sleep quality is associated with alcohol use and functional capacity in chinese patients with gout: a cross-sectional study
Authors: T Fu, R Yin, L Zhang, Q Zhang, Y Xia, J Ji, Z Da, X Zhu, L Li, Z Gu
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Poor sleep quality is common in patients with chronic diseases and may lead to disease aggravation and decreased quality of life. The increasing prevalence of poor sleep in individuals with chronic medical conditions is associated with adverse demographic, clinical, and psychological characteristics. However, there are currently no known reported studies related to the sleep quality of gout patients. <h3>Objectives</h3> This study aims to evaluate the prevalence of poor sleep quality and investigate the contributors of poor sleep in Chinese gout patients. <h3>Methods</h3> A self-report survey was administered to 226 gout patients and 232 healthy individuals using the Pittsburgh Sleep Quality Index (PSQI) for sleep quality, the Patient Health Questionnaire (PHQ-9) for depression, and the Generalized Anxiety Disorder (GAD-7) questionnaire for anxiety. Gout patients completed the 10 cm Visual Analog Scale (VAS) for total pain, and the Health Assessment Questionnaire-Disability Index (HAQ-DI) for functional capacity. Blood samples were taken to examine the level of uric acid (UA). Independent samples t-tests, Chi square analyses, and logistic regression were used to analyze the data. <h3>Results</h3> Our results found that the prevalence of poor sleep (PSQI≥5) was 55.3% and the mean global score of PSQI was 6.69 (SD 3.48) in patients, which were significantly higher than the controls (17.7% and 3.83 (SD 1.88), respectively). There were significant correlations among alcohol use, HAQ-DI, PHQ-9, GAD-7 and sleep quality in gout patients. Patients with yellow rice wine and wine use preferred to have better sleep quality. While, disease stage was associated with hypertension, total pain, number of tophi, presence of tender joints and swollen joints. Meanwhile, logistic regression models identified alcohol use and depression as predictors of poor sleep quality. <h3>Conclusions</h3> More than half of Chinese gout population suffered from poor sleep, which significantly higher than healthy individuals. These findings suggested medical personnel should pay more attention to the sleep quality of gout patients, especially those with depression. Additionally, it is beneficial for the patients with normal UA level to take moderate yellow rice wine and wine to improve their sleep quality. <h3>Acknowledgements</h3> This study was supported by Grants from the Chinese National Natural Science Foundation (no. 81671616 and 81471603). <h3>Disclosure of Interest</h3> None declared
SAT0586 Relationship between core stabilization and low back pain in young people
Authors: E Mete, V Akduman, I Demirbuken, G Ogren
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Low Back Pain (LBP) is a very common health problem that affects people of all ages. It has been observed that the increase in lumbar stabilization is effective in reducing back pain risk. A combination of local and global stability system is used to describe to core stability which is a key factor for enhancing lumbar stabilization. Exercise training focused on these groups of muscles could contribute to pain alleviation and spinal functional improvement. <h3>Objectives</h3> The aim of the study was to define relationship between core stabilization and low back pain in young people who were suffering from low back pain. <h3>Methods</h3> 290 individuals (144 male, 146 female), between 18 and 25 years of age were included in this study. Disability arising from low back pain was identified by using the Oswestry disability index, consisting of 10 questions with 6 choices (0–5 points for each question). The higher score is associated with more low back pain. The period of core stabilization was determined using Plank test in which the body is stand flat from shoulder to heels on foot and forearm and Side Plank test in which sitting on the forearm and standing on one side of the body with the legs parallel and the feet perpendicular and the body is held flat from the shoulder to the heels. The duration of ability to maintain Plank test was measured by a chronometer. Spearman correlation test used for statistical analyzing. <h3>Results</h3> In this study, the average of Plank test duration was 76.9±44.2 (sec), while the mean of the Side Plank test duration was 43.9±28.2 (sec) and Oswestry disability index total score was 6.3±5.5. A weak negative correlation was found between the Plank test and the Oswestry disability index (p=0,03; r =-0,111). And negatively correlated between the Side Plank and the Oswestry disability index (p&gt;0.05). On the other hand, there was a positively modarate correlation between the Plank test and the Side Plank test (p=0,00; r =0,656). There was a weak negative correlation between age and Oswestry disability index (p=0,014; r =- 0,151). <h3>Conclusions</h3> Results of the study indicated that increasing the duration of stabilization reduces the low back pain. For this reason, core muscles deserve a great deal of interest in order to reduce the problem of low back pain which is common among young population. <h3>References</h3> Kibler, W. Ben, Joel Press, and Aaron Sciascia. The role of core stability in athletic function. Sports medicine 36.3 (2006): 189–198. Zazulak, Bohdanna T., et al. The effects of core proprioception on knee injury: a prospective biomechanical-epidemiological study. The American journal of sports medicine (2007). <h3>Disclosure of Interest</h3> None declared
THU0264 Responsiveness of lupuspro v1.8 among chinese patients with lupus
Authors: CC Mok, J Block, M Jolly
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> LupusPRO v1.7 is a patient reported outcome tool for patients with systemic lupus erythematosus (SLE) that has undergone psychometric validation and responsiveness studies in the US. <h3>Objectives</h3> To report results on responsiveness of LupusPRO among Chinese patients with SLE. <h3>Methods</h3> 430 patients with SLE meeting the ACR classification criteria were recruited in Hong Kong, China at a single center for this observational study. LupusPRO scores from two visits one year apart were analyzed for responsiveness and Minimal Clinically Important Difference (MCID) against patient report and physician assessed anchors of changes in health. Two patient reported anchors were used (Global change in health and item 2 of Short Form 36 form). Physician assessed anchors of change in health were disease activity (Physician global assessment-PGA, SELENA-SLEDAI) and damage (SLICC-SDI/ACR). Change in PGA of ≥0.3 and SELENA-SLEDAI of ≥4 in either direction was used to define worsening in disease activity. Our primary outcomes of interest were was summary HRQOL and HRQOL domains, as non HRQOL domains tend not to change over short time periods. Analysis of variance was used to compare changes in LupusPRO summary and domain scores against the anchors. <h3>Results</h3> Mean (SD) age of participants was 42 (14) years. Ninety five percent were women. Mean (SD) PGA, SELENA-SLEDAI and SDI at baseline were 0.5 (0.5), 2.9 (3.0) and 0.7 (1.2) respectively. Summary HRQOL, and HRQOL domains (Lupus Symptoms, Physical Health, Pain-Vitality, Emotional Health and Body Image) were responsive to changes in patient reported and physician assessed health status (disease activity and damage) (Table 1). Procreation and Cognition domains showed responsive trends with patient reported change in health status, while Lupus Medications domain was responsive additionally to changes in Damage. <h3>Conclusions</h3> LupusPRO summary HRQOL and HRQOL domains show responsiveness to changes in patient-reported and physician assessed changes in health status in this observational study among Chinese SLE patients. Results support inclusion of LupusPRO into larger clinical trials to allow for robust estimates of responsiveness. <h3>Disclosure of Interest</h3> None declared
AB1061 The high doses golimumab bring better suppression of ultrasonographic synovial inflammation in patients with rheumatoid arthritis?
Authors: T Okano, K Inui, Y Sugioka, K Mamoto, T Koike, H Nakamura
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Biologic diseasemodifying antirheumatic drugs (bDMARDs) that target cytokines and cytokine receptors such as tumor necrosis factor (TNF)alpha and interleukin (IL)6 have been established as a standard therapy of rheumatoid arthritis (RA) for patients with conventional systemic DMARDs, such as methotrexate (MTX), resistant disease. Golimumab, one of the bDMARDs, is an antibody targeting to TNF-alpha. In Japan, we can choose the dose of golimumab 50mg or 100mg according to the disease activity. Recent advance of ultrasound (US) equipment allows obtaining high-quality gray-scale (GS) imaging and sensitive power Doppler (PD) assessment, especially at small joints of the hands and feet. To date, US is the most sensitive imaging modality available in daily rheumatology practice for the assessment of residual synovitis. <h3>Objectives</h3> The aim of this study was to compare the ultrasound findings between patients with rheumatoid arthritis (RA) treated by golimumab 100mg and 50mg. <h3>Methods</h3> Patients with RA treated by golimumab were consecutively included. Ultrasound examination was performed at 52 synovial sites, bilateral first to fifth MCP, first IP and second to fifth PIP joints, first to fifth flexor tendon and wrists, 2nd and 6th compartment of extensor tendons and first to fifth MTP joints, by using HI VISION Ascendus (Hitachi Medical Corporation, Japan) with a multifrequency linear transducer (18–6 MHz). The GS and PD signals were scored in each synovial site using a semi-quantitative scale from 0 to 3. <h3>Results</h3> Fifty-five patients with RA (46 female, mean age: 64.2±12.1 years) were included and analyzed. In comparison between the dose of Golimumab at the time of ultrasound examination, disease activity (DAS28-CRP) was significantly higher in 100mg group (100mg, n=15: 3.6±1.0, 50mg, n=40: 2.3±0.9; p&lt;0.001), but ultrasound findings were not significantly different between golimumab 100mg and 50mg groups. In patients achieving remission, ultrasound findings were not different between 100mg started and 50mg started groups. <h3>Conclusions</h3> Even patients have high disease activity, golimumab 100mg suppress the synovitis and tenosynovitis very well. In the condition where disease activity was sufficiently controlled, there was no difference in the synovitis findings of ultrasound at the dose of golimumab. <h3>Acknowledgements</h3> We wish to thank Setsuko Takeda, Ayumi Hashimoto, Emi Yamashita, Rika Morinaka, Hatsue Ueda and Tomomi Iwahashi for their special efforts as a sonographer and collecting data. <h3>Disclosure of Interest</h3> None declared
SAT0714 Increased risk of opportunistic infection in the early stage of rheumatoid arthritis
Authors: H Kim, S-K Cho, MJ Kim, GY Ahn, HH Kwon, D Kim, J Lee, S-C Bae, Y-K Sung
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> The increased risk of opportunistic infections (OIs) in rheumatoid arthritis (RA) patients who started biologic disease modifying anti-rheumatic drugs (DMARDs) has been well known. However, it has not been studied regarding the increased risk of OIs in the early stage of RA. <h3>Objectives</h3> To study the increased risk of incidence rate (IR) of OIs in early RA patients compared with established RA patients, and to evaluate the risk factors for developing the OIs in the early stage of RA. <h3>Methods</h3> Retrospective cohorts of early and established RA patients were conducted independently using the Korean National Healthcare claims database. Early RA patients (n=14,081) were identified in 2010 having disease free period for 1 year before index date, and receiving continuous treatment for over three years. Established RA patients (n=226,838) were recruited between 2010 and 2012 with using the ICD10 code of RA and any DMARD use. Follow-up started on the index date and ended on the data of the development of OIs, at 12 months, or at the time of death. The incidence rates of OIs were compared between two groups by calculating incidence rates ratio (IRR) and standardized incidence ratio (SIR) for overall or each OIs. The multivariable regression model was used to evaluate the risk factors for OIs in the early stage of RA. <h3>Results</h3> The IRs of overall OI in early and established RA patients were 3.81 (95% CI 3.52–4.11)/100PY and 3.67 (95% CI, 3.59–3.74)/100PY, respectively. The SIR for overall OIs in early RA patients was 1.14 (95% CI, 1.05–1.23). The herpes zoster (SIR 1.12, 95% CI 1.03–1.22) and candidiasis (SIR 2.40; 95% CI 1.55–3.54) were commonly affected in the early stage of RA patients. Older age more than 50 years old [50&lt;age≤60 (OR 1.74, 95% CI 1.30–2.33), 60&lt;age≤70 (OR 1.85, 95% CI 1.36–2.52), 70&lt;age (OR 1.89, 95% CI 1.34–2.68)], more comorbidities [one comorbidities (OR 1.53, 95% CI 1.24–1.89), ≥2 of comorbidities (OR 1.84, 95% CI 1.47–2.29)], and corticosteroid ≥5mg per day (OR 1.38, 95% CI 1.13–1.69) were associated with increased risk of OIs in the early stage of RA patients. <h3>Conclusions</h3> The incidence of OIs is increased in early stage of RA patients compared with established RA patients. Old age, comorbidities, high corticosteroid dose were related with the development of OI. Physicians should be aware of the possible occurrence of OIs in early stage of RA treatment. <h3>Disclosure of Interest</h3> None declared
SP0126 The vessel wall in imids – new emerging vascular markers
Authors: Z Szekanecz
Journal: Annals of the Rheumatic Diseases (2017)

Cardiovascular disease dependent on inflammatory accelerated atherosclerosis leads to increased mortality in rheumatoid arthritis (RA). In addition to traditional, Framingham risk factors, several immuno-inflammatory cells, mediators and molecules may link atherosclerosis to arthritis. Among immune cells, primarily TH1 cells, as well as endothelial cells play a crucial role in synovial and vascular inflammation. Various cell surface molecules, such as adhesion receptors, CD40-CD40 ligand or members of the RANK-RANK ligand-osteoprotegerin system, as well as soluble pro-inflammatory cytokines, chemokines, autoantibodies and proteases have been implicated in RA and vascular damage. The early assessment of atherosclerosis and early intervention would decrease cardiovascular risk in RA. <h3>Disclosure of Interest</h3> None declared
AB0673 Testing for antibodies specific to fibrillarin (U3 RNP) shows added value for diagnosis of systemic sclerosis
Authors: I Gehring, S Sjölander, P Höpfl, S Swiniarski, L Vinderslev Iversen, G Gallo
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Systemic sclerosis (SSc) is a heterogeneous and often systemic autoimmune disorder characterised by specific autoantibody subsets. The disease is associated with anti-nuclear antibodies (ANA) and the detection of each of the autoantibodies is useful during diagnosis. Most SSc patients are positive for anti-centromere or anti-Scl70 antibodies. The presence of more rare antibodies to, e.g. Fibrillarin (U3 RNP), RNA-polymerase III and PM-Scl are often indicative of a systemic or a limited skin involvement. <h3>Objectives</h3> In this in-house study the prevalence, and clinical sensitivity and /specificity of anti-Fibrillarin antibodies in a subset of patients diagnosed with SSc was investigated. The major aim was to find out whether Fibrillarin testing would identify patients which are negative for standard parameters and therefore add value forin the diagnosticis workup for patients with suspected SSc. <h3>Methods</h3> Sera from 187 SSc patients, 53 blood donors and 177 disease controls were analysed for the presence of antibodies to CENP, Scl-70s, PM-Scl, RNA Pol III and Fibrillarin using the EliA platform (Thermo Fisher Scientific, Freiburg, Germany). <h3>Results</h3> In 149 out of the 187 patients one or more of the tested parameters were detected. Fibrillarin was identified in 7 out of the 149 patients including 6 solely positive for Fibrillarin. Overall sensitivity within this study is 79,68% with an overall specificity of 92,17%; for Fibrillarin sensitivity of 3,74% and specificity of 98,70% was shown within this cohort. <h3>Conclusions</h3> Increased diagnostic sensitivity was shown in this cohort of 187 patients with SSc by adding the analysis of antibodies against Fibrillarin. Testing allowed additional identification of 6 SSc patients which correlates to an increase of 3,74% in sensitivity. <h3>References</h3> Arthritis Res Ther 2003, 5:80–93. Rheumatology 2001;40:1157–1162. <h3>Disclosure of Interest</h3> None declared
AB1069 Shoulder ultrasonography in diabetic patients – is there damage with no clinical sign?
Authors: VC Iorgoveanu, V Bojinca, R Malitchi, M Gheorghe, C Ionescu, R Ionescu
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Degenerative lesions in shoulder rises exponentialy with age and diabetes was found to be associated with shoulder pain [1,2]. <h3>Objectives</h3> To evaluate the prevalence and type of lesions of shoulder in diabetic patients with no pain using ultrasound (US). <h3>Methods</h3> We included consecutive patients with diabetes with no pain or clinical tumefaction in shoulder. US was performed in both shoulders using the standard scanning planes and dynamic maneuvers. Clinical data as fasting glycemia, BMI, treatment were recorded. <h3>Results</h3> Forty two shoulders were examined in 21 consecutive patients (mean age 67.92+/-7.35 years, weight 81.75 +/- 13.57 kg, BMI 25+/-2 kg/m<sup>2</sup>, fasting glycemia 151.85+/-33.72mg/dl) with diabetes diagnosis mean 5.33 years +/- 5.99. Majority of patients were under treatment with oral antidiabetics (58.3%). Degenerative lesions were found in subscapular (SSc) 33.3% and supraspinatus (SpS) 8.3%) tendons as well as intratendinous micro ruptures with calcifications (33.3% bilateral calcifications in SSc, SpS). Impingement syndrome was objectified in 16.6% of examinations. Minimal inflammatory signs as: sub-acromion sub deltoidian bursitis in 50% (minimum in 33.3%, 8.3% bilateral) and long head biceps tenosynovitis in 58.33% (8.3% minimal Doppler signal). 83.3% showed humeral irregularities and also erosions were found (8.3%). <h3>Conclusions</h3> Degenerative and minimal inflammatory lesions in shoulder of diabetic patients exist with no clinical sign (pain, tumefaction). Ultrasonography might be an usefull technique to confirm these alterations before the appearance of symptoms. <h3>References</h3> Thomas SJ, McDougall C, Brown ID, et al. Prevalence of symptoms and signs of shoulder problems in people with diabetes mellitus. J Shoulder Elbow Surg. 2007;16:748–751. Abate M, Schiavone C, Salini V. Sonographic evaluation of the shoulder in asymptomatic elderly subjects with diabetes. BMC Musculoskelet Disord. 2010;11:278. <h3>Disclosure of Interest</h3> None declared